ProtecT Trial 15-Year Follow-Up May be ‘Very Important’ for Prostate Cancer

Video

Fifteen-year results of the ProtecT prostate cancer trial may support the findings of the study’s 10-year follow-up data, according to an expert from Dana-Farber Cancer Institute.

In an interview with CancerNetwork® during the 16th Annual Interdisciplinary Prostate Cancer Congress® and Other Genitourinary Malignancies, hosted by Physicians’ Education Resource®, LLC (PER®), Anthony V. D’Amico, MD, PhD, spoke of the anticipated 15-year follow-up data from the ProtecT trial (NCT02044172) evaluating outcomes following active monitoring, radical prostatectomy, and external-beam radiotherapy for patients with prostate cancer.

With a median follow-up of 10 years, investigators of the ProtecT trial concluded that mortality was low regardless of assigned treatment. Additionally, metastases developed in more patients in the active-monitoring group with 6.3 events per 1000 person-years (95% CI, 4.5-8.8) compared with 2.4 events per 1000 person-years (95% CI, 1.4-4.2) for those receiving surgery and 3.0 events per 1000 person-years (95% CI, 1.9-4.9) for those receiving radiotherapy (P = .004).

Disease progression rates in each respective group were 22.9 events per 1000 person-years (95% CI, 19.0-27.5), 8.9 events per 1000 person-years (95% CI, 6.7-11.9), and 9.0 events per 1000 person-years (95% CI, 6.7-12.0; P <.001).

D'Amico, a professor and chair of genitourinary radiation oncology at Brigham and Women’s Hospital and Dana-Farber Cancer Institute, suggested that the 15-year data from the ProtecT study might be consistent with those reported in the 10-year follow-up.

Transcript:

Something that we're all awaiting that will be very important is the 15-year results of the ProtecT trial, which is a study that [randomly assigned] patients between monitoring, radical prostatectomy, radiation, and hormonal therapy. At 10 years, there was a difference in the metastatic rate, doubling the metastatic rate in the active monitoring as opposed to treatment arms, with no difference between the 2 treatments.

The 15-year results will be informative because we know 10-year results are still early. I suspect that the 15-year results might support the 10-year findings. But that's something we're awaiting, and I know that that is supposed to be available in the coming weeks.

Reference

Hamdy FC, Donovan JL, Lane JA, et al. 10-year outcomes after monitoring, surgery, or radiotherapy for localized prostate cancer. N Engl J Med. 2016;375:1415-1424. doi:10.1056/NEJMoa1606220

Related Videos
Investigators are assessing the use of IORT in patients with borderline resectable or unresectable pancreatic cancer as part of the phase 2 PACER trial.
The approval for epcoritamab in patients with R/R follicular lymphoma was supported by encouraging efficacy findings from the phase 1/2 EPCORE NHL-1 trial.
A phase 1/2 trial assessed the use of menin inhibitor DSP-5336 in patients with acute leukemia overexpressing HOXA9 and MEIS1.
A phase 1 trial assessed the use of PSCA-directed CAR T cells in patients with metastatic castration-resistant prostate cancer.
A pooled analysis trial assessed the impact of acalabrutinib in patients with chronic lymphocytic leukemia across treatment lines.
Findings from a phase 1 study may inform future trial designs intended to yield longer responses with PSCA-targeted CAR T cells.
A phase 1 trial assessed the use of PSCA-directed CAR T cells in patients with metastatic castration-resistant prostate cancer.
Kamran Idrees, MD, MSCI, MMHC, FACS, discusses how factors such as vessel involvement can influence the decision to proceed with surgical therapy.
relapsed or refractory mantle cell lymphoma, glofitamab, Obinutuzumab, phase 1/2 study, NCT03075696, Tycel J. Phillips, MD
Milad Baradaran, PhD, DABR, outlines the design of Mobetron as an option for administering intraoperative radiation therapy in pancreatic cancer care.
Related Content